metsera glp 1 Is This the First Real Threat to Lilly and Novo? Metsera's Stunning New Data for Once Monthly Amylin Agonist Pfizer Metsera Acquisition and GLP-1

Some varieties include natural flavors in the ingredients, which may concern some users

Adherence rates: a potential obstacle

Biomarkers and Genetic Predispositions That Influence Eligibility Conversations While BMI and health history form the foundation of eligibility, emerging research suggests genetic variations in GLP-1 receptor pathways influence individual response variability

People with a personal or family history of allergies, eczema, or psoriasis may be at higher baseline risk for skin reactions to any new medication

A 2025 letter in Diabetes Care argues that microdosing via multidose pens can help patients who struggle with gastrointestinal side effects by allowing smaller, incremental dose adjustments, though the authors emphasize this is a pragmatic, clinician-directed strategy

Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the fda adverse event reporting system